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Background

Therapeutic decisions in atrial fibrillation (AF) are often influenced by assessment of bleeding risk. However, existing
bleeding risk scores have limitations.
.....................................................................................................................................................................................
Objectives
We sought to develop and validate a novel bleeding risk score using routinely available clinical information to predict
major bleeding in a large, community-based AF population.
.....................................................................................................................................................................................
Methods
We analysed data from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF), a prospective registry that enrolled incident and prevalent AF patients at 176 US sites. Using Cox proportional hazards
regression, we identified factors independently associated with major bleeding among patients taking oral anticoagulation (OAC) over a median follow-up of 2 years (interquartile range ¼ 1.6 – 2.5). We also created a numerical
bedside risk score that included the five most predictive risk factors weighted according to their strength of association with major bleeding. The predictive performance of the full model, the simple five-item score, and two existing
risk scores (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly, HAS-BLED, and anticoagulation and risk factors in atrial fibrillation, ATRIA) were
then assessed in both the ORBIT-AF cohort and a separate clinical trial population, Rivaroxaban Once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial
fibrillation (ROCKET-AF).
.....................................................................................................................................................................................
Results
Among 7411 ORBIT-AF patients taking OAC, the rate of major bleeding was 4.0/100 person-years. The full continuous
model (12 variables) and five-factor ORBIT risk score (older age [75+ years], reduced haemoglobin/haematocrit/
history of anaemia, bleeding history, insufficient kidney function, and treatment with antiplatelet) both had good ability
to identify those who bled vs. not (C-index 0.69 and 0.67, respectively). These scores both had similar discrimination,
but markedly better calibration when compared with the HAS-BLED and ATRIA scores in an external validation population from the ROCKET-AF trial.
.....................................................................................................................................................................................
Conclusions
The five-element ORBIT bleeding risk score had better ability to predict major bleeding in AF patients when compared
with HAS-BLED and ATRIA risk scores. The ORBIT risk score can provide a simple, easily remembered tool to support
clinical decision making.
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Introduction
Anticoagulation therapy can clearly reduce the risk of stroke and
systemic emboli when used in atrial fibrillation (AF) patients,1,2 yet
clinicians and patients must often consider these benefits vs. the risk
of major bleeding.3,4 In clinical practice, simple scores can serve as a
useful tool to support providers to estimate the risks of stroke as
well as for major bleeding.5 – 8 However, existing bleeding scores,
including hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly (HAS-BLED)9 and anticoagulation and risk factors in
atrial fibrillation (ATRIA),10 were based on small numbers of
events,11 have shown inconsistent performance in external populations,12,13 and may require data elements that are not accessible for
all oral anticoagulation (OAC) users.14 – 16 Therefore, there remains
a need for a simple, accurate risk score that uses readily available
clinical information to predict the occurrence of major bleeding in
AF patients receiving contemporary anticoagulation.
Using data from the national Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry, we
constructed a full continuous predictive model as well as a simple
risk score for major bleeding among patients who were taking
OAC therapy. We compared the performance of this novel score
to that of two other major bleeding models (HAS-BLED and ATRIA) in the ORBIT-AF population as well as in an external validation
sample of those enrolled in Rivaroxaban Once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET-AF),
a randomized trial of anticoagulation therapy for stroke prevention.

splines. Missing data were handled with single imputation. Imputed values were obtained by the Markov chain Monte Carlo method or regression methods.19 We used a backwards selection approach with a stay
criterion of P , 0.05 to generate the full continuous predictive model.
To create the simple ORBIT score, we retained five predictors from the
full model with the highest individual chi-square statistics. Point values
were assigned to each predictor according to its strength of association
with major bleeding.
We assessed model performance by examining discrimination and
calibration at 2 years of follow-up in the ORBIT-AF cohort. Discrimination was evaluated using the C-index,20 which quantifies the ability of
the model to correctly distinguish between patients who do and do not
experience a major bleeding event. Calibration was evaluated by plotting major bleeding events rates per 100 patient-years and 95% CIs observed in the external validation cohort vs. those previously published
from the original derivation cohorts for each discrete score point value.
As a sensitivity analysis, we examined discrimination of the ORBIT score
for prediction of intracerebral haemorrhage (ICH) using the C-index.
Because bleeding rates may be higher among new starts than long-term
warfarin users, we conducted a sensitivity analysis assessing ORBIT
score performance among patients who were taking warfarin for
,6 months.

Comparison with existing scores
We compared the predictive performance of the ORBIT score to that
of two existing bleeding scores, HAS-BLED and ATRIA. The HAS-BLED
score was derived from 53 major bleeding events occurring in 3978
patients in the EURO Heart Survey on AF.21 The ATRIA score was derived from 461 major bleeds occurring in 9186 adults with AF enrolled
in Kaiser Permanente healthcare system in Northern California.10

External validation

Methods
We used data from ORBIT-AF, a prospective study of 10 132 incident
and prevalent AF patients (2010 – 2012), to construct a risk score for
major bleeding.17 Briefly, the ORBIT-AF Registry is a national, outpatient
registry of patients with electrocardiographically confirmed AF at 176
sites in the USA. We excluded patients who were not taking OACs
at baseline (N ¼ 2419) and patients without follow-up data (N ¼ 302)
for a final analytic population of N ¼ 7411. Major bleeding was defined
according to International Society on Thrombosis and Haemostasis
criteria: (i) fatal bleeding and/or (ii) symptomatic bleeding in a critical
area or organ (intracranial, intraspinal, intraocular, retroperitoneal,
intra-articular or pericardial, or intramuscular with compartment
syndrome), and/or (iii) bleeding causing a fall in haemoglobin level of
20 g L21 (1.24 mmol L21) or more, or leading to transfusion of two
or more units of whole blood or red cells.18 Patient characteristics
were described as frequency/percent for categorical variables and medians/interquartile ranges (IQRs) for continuous variables. The characteristics were compared using the chi-square test for categorical variables
and the Wilcoxon rank sum test for continuous variables.
We constructed a multivariable Cox regression model with time to
major bleeding over 2 years of follow-up as the outcome. Candidate
variables for the model were chosen from the list of variables collected
at the baseline study visit based on existing evidence and clinical relevance. The full candidate covariate list is available in Supplementary materials online. Additionally, we accounted for within site clustering of
patients using empirical standard errors. All continuous variables were
evaluated for non-linearity with the outcome, and those not meeting the
linear relationship criterion (P , 0.05) were accounted for using linear

We also evaluated the accuracy of the ORBIT, HAS-BLED, and ATRIA
scores in an external AF population, ROCKET-AF, an international, randomized, double-blind, event-driven trial of 14 264 patients comparing
rivaroxaban (20 mg daily) to dose-adjusted warfarin. Each score was recreated according to definitions given in the original derivation cohorts,
using baseline values from the first trial visit, or from the first study visit
in ORBIT-AF. Score components not collected in ROCKET-AF or
ORBIT-AF were approximated using available data or contributed 0
points to the score if no approximation was available. The full list of
definitions used to generate the scores in each dataset is provided in
Supplementary materials online.
Statistical analysis was performed using SAS software (version 9.3,
Cary, NC). All P-values presented are two sided, and P , 0.05 was considered to be statistically significant for all analyses. All ORBIT-AF study
participants provided written informed consent prior to study entry.
The ORBIT-AF Registry was approved by the Duke Institutional Review
Board (IRB), and participating sites obtained approval from local IRBs as
needed prior to entering patient data.

Results
Of 7411 ORBIT-AF patients taking OAC at baseline, the median age
was 75 years (IQR 68 – 82) and 42.4% were female. There were
93.5% treated with warfarin and 6.5% with dabigatran. Over a median of 2 years (IQR 1.6– 2.5) of follow-up, 581 (7.8%) major bleeding events occurred. Patients who experienced a major bleeding
event during follow-up were on average older, more likely to be
white, and more likely to be female than those who did not (Table 1).
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Table 1 Baseline characteristics by major bleeding
during follow-upa
P-value**

No major
bleed
(N 5 6830;
92.2%)

Major bleed
(N 5 581;
7.8%)

75 (67–81)

78 (71– 83)

57.9

53.9

0.06

89.4

91.6

0.06

34.8

57.5

,0.0001

Hypertension

84.5

89.3

0.0019

Diabetes
Current smoker

30.3
5.3

33.7
6.5

0.08
,0.0001

Variable

................................................................................
Demographics
Age (years)
(median) IQR
Male gender
White race
Comorbidities
Anaemia/
abnormal Hgb/
Hct

,0.0001

GI bleed

7.4

15.5

,0.0001

Prior stroke
CHF

9.2
33.8

13.1
44.9

0.002
,0.0001

MI

15.4

20.5

0.001

Osteoporosis/hip
fracture

14.4

20.3

0.0001

COPD
History of cancer

15.7
23.3

24.4
30.8

,0.0001
,0.0001

49.1
95.0

,0.0001
0.14

Antithrombotic therapy
Antiplatelets
Warfarin
Dabigatran

37.0
93.4
6.6

5.2

0.18

eGFR,60 mg/dL/
1.73 m2

34.0

48.4

,0.0001

CHA2DS2-VASC,
median (IQR)

4.0 (3.0– 5.0)

5.0 (4.0–6.0)

,0.0001

HAS-BLED, median
(IQR)

2.0 (1.0– 2.0)

2.0 (2.0–3.0)

,0.0001

ATRIA bleeding
score, median
(IQR)

3.0 (1.0– 4.0)

4.0 (3.0–6.0)

,0.0001

IQR, interquartile range; hgb, haemoglobin; hct, haematocrit; GI, gastrointestinal;
CHF, congestive heart failure; MI, myocardial infarction; COPD, chronic
obstructive pulmonary disease; eGFR, estimated glomerular filtration rate.
a
Per cent or value.
**P-values from chi-squared tests for categorical variables and Kruskal–Wallis tests
for continuous variables.

Patients experiencing a major bleed had a higher comorbidity burden than those who did not, with higher rates of anaemia, chronic
obstructive pulmonary disease (COPD), congestive heart failure,
hypertension, diabetes, sleep apnoea, and chronic kidney disease.
Compared with those without a major bleed, patients with a bleeding event were more likely to be smokers, have a history of frailty,
and be living with assistance than those who did not. Estimated
CHA2DS2-VASC stroke risk was higher among patients who had a
major bleed [median ¼ 5 (IQR 4 – 6) vs. 4; (IQR ¼ 3 – 5)]. Use of
other antithrombotics was higher among patients who experienced

a major bleed than those who did not (49.1 vs. 37.0%), with aspirin
representing the majority of other antithrombotic use (34.7%
among all patients with no major bleeding and 45.8% among all
patients with major bleeding).
The full continuous ORBIT bleeding model included the following
independent predictors of major bleeding: antiplatelet therapy (aspirin, ticagrelor, prasugrel, clopidogrel, fixed dose combination
aspirin-dipyridamole), prior bleeding (any history of gastrointestinal,
intracranial or haemorrhagic stroke documented at the baseline
study visit), age, estimated glomerular filtration rate (eGFR), haematocrit, history of CHF, history of cancer, COPD, history of anaemia/
abnormal haemoglobin (,13 mg/dL for males and ,12 mg/dL for
females) or haematocrit (,40% for males and ,36% for females),
history of hip fracture or osteoporosis, and smoking status (recent/
former or current). Following construction of the full model, we
created a simple, five-factor numerical bleeding risk score from
the five strongest predictors termed ORBIT (older (75 years or older); reduced haemoglobin (,13 mg/dL in men and ,12 mg/dL in
women), haematocrit (,40% in men and ,36% in women) or history of anaemia; bleeding history; insufficient kidney function
(eGFR , 60 mg/dL/1.73 m2); and treatment with an antiplatelet
agent. We assigned point values based on the log scale according
to the magnitude of modelling coefficient representing each variable’s association with major bleeding.22 Reduced haemoglobin/
haematocrit/history of anaemia and bleeding history received two
points, and insufficient kidney function, treatment with antiplatelets,
and older age received one point. Table 2 shows the associations between each score component and major bleeding risk in the multivariable model. Reduced haemoglobin/anaemia was most strongly
associated with major bleeding, followed by bleeding history, treatment with antiplatelets, insufficient kidney function, and older age.
As shown in Table 3, there was a broad distribution of ORBIT major
bleeding risk scores among patients in the study population, with a
bleeding risk score of 1 (22.9%) being the most common. Observed
major bleeding rates increased with increasing risk score.
After classifying patients into low (ORBIT scores 0– 2), medium
(ORBIT score 3), and high (ORBIT score 4 or greater) categories,
we compared bleeding rates within estimated risk groups. The largest proportion of patients were classified as low bleeding risk
(58.6%), followed by high risk (23.2%), and medium risk (18.2%).
Observed bleeding rates per 100 patient-years increased with increasing risk group, from 2.4 in the low-risk group, to 4.7 in the medium risk group, and 8.1 in the high-risk group (Table 3).
Table 4 displays the discrimination of each of the four models (full
continuous ORBIT model, the five-item ORBIT score, HAS-BLED,
and ATRIA) in the ORBIT-AF cohort and the ROCKET-AF trial
population. In the ORBIT-AF cohort, the full continuous ORBIT
model showed the best discrimination, followed by the simple
ORBIT score, the ATRIA score, and the HAS-BLED score. In a sensitivity analysis, the five-item ORBIT score showed good performance for prediction of ICH (C-index ¼ 0.69; 95% CI ¼ 0.63, 0.74).
In a second sensitivity analysis restricting the population to patients
taking warfarin for ,6 months, ORBIT score performance was similar (0.65; 0.57, 0.74) to that observed in the overall population.
We used the ROCKET-AF study as a validation sample. Over 21
769 person-years of follow-up (median ¼ 1.9 years), 772 major bleeds
occurred in ROCKET-AF (3.5/100 person-years). Discrimination was
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Table 2 Association between outcomes registry for better informed treatment risk score components and major
bleeding
Variable

Hazard ratioa

95% CI HR

Chi-square-value

Points

Older age
Reduced haemoglobin/Hct/anaemia

1.38
2.07

1.17–1.61
1.74–2.47

15
66

1
2

Bleeding history

1.73

1.34–2.23

18

2

Insufficient kidney function
Treatment with antiplatelets

1.44
1.51

1.21–1.72
1.30–1.75

17
30

1
1

...............................................................................................................................................................................

a
Outcomes registry for better informed treatment bleeding risk score components (point value) ¼ older than 74 (1), reduced haemoglobin/anaemia (2), bleeding history (2),
insufficient kidney function (,60 mL/min/1.73 m2) (1), treatment with antiplatelet (1). Abnormal haemoglobin (,13 mg/dL for males and ,12 mg/dL for females) or haematocrit
(,40% for males and ,36% for females).

slightly reduced for all scores when assessed in the ROCKET-AF trial
population than seen in the ORBIT-AF community-based cohort.
However, predictive accuracy patterns for the various scores were
similar in ROCKET-AF population as seen in the ORBIT-AF population. The highest discrimination was seen with the full continuous
ORBIT model, followed by the simple ORBIT score, ATRIA and
HAS-BLED.
Results from the model calibration analysis comparing observed
bleeding rates in ROCKET-AF with reported bleeding rates in the
original derivation populations for ORBIT, HAS-BLED, and ATRIA
scores are displayed in Figure 1. The ORBIT score displayed superior
calibration compared with the remaining two scores, followed by
HAS-BLED and ATRIA. The HAS-BLED score showed relatively
poor calibration for low-risk score strata. The ATRIA score showed
poor calibration for most risk groups.

Discussion
Physician concerns about major bleeding represent a key barrier to
optimal anticoagulation use in AF.23 However, prior studies have
clearly demonstrated that physician estimates of bleeding risk tend
to be inaccurate and lower than existing scores.24 Using the
ORBIT-AF registry community-based population, we identified factors associated with major bleeding on OAC and created a simple
five-factor risk score with the acronym ORBIT. The predictive accuracy of the novel risk score performed well relative to two other
major bleeding models (HAS-BLED and ATRIA) in an external clinical trial population, ROCKET-AF. Combined, we believe the ORBIT
bleeding risk score could have application as a simple aid to clinical
decision making in routine practice.
The recent introduction of simple tools for estimation of bleeding
risk in AF has resulted in heightened interest in their comparative
statistical performance and clinical utility. Two prior studies examined the prognostic utility of the two commonly used AF bleeding
risk scores, ATRIA and HAS-BLED, in the warfarin14 and idraparinux
arms25 of the Evaluating the Use of SR34006 Compared with Warfarin or Acenocoumarol in Patients With Atrial Fibrillation trial. In
both studies, each score showed only modest discrimination
(c-indices 0.6) for clinically relevant bleeding, major bleeding, or
death. While study authors concluded that HAS-BLED showed superior performance for clinically relevant bleeding, predictive

performance was similar across scores for the major bleeding endpoint. As has been noted previously,15 risk of clinically relevant
bleeding has may have less impact on anticoagulation decisions
than risk of major bleeding and may represent a less specific endpoint for evaluation of score performance than major bleeding
events. In addition, AF clinical trial populations are highly selected,
and may exclude patients at the upper end of the bleeding risk spectrum. In our analysis, all three risk scores showed better discriminative performance in ORBIT-AF than in ROCKET-AF, likely due to
more stringent trial inclusion criteria that results in a more homogenous, less representative patient population. The ATRIA and
HAS-BLED scores also showed poor calibration in ROCKET-AF,
indicating these scores may have less predictive accuracy in more
narrow patient populations.
Our results are similar to those from prior studies showing similar, but modest performance of bleeding risk scores in observational
cohorts. In an analysis of 7156 patients diagnosed with non-valvular
AF in a four-hospital institution, Lip and colleagues reported that
discrimination was modest and similar across six bleeding risk
scores, including ATRIA and HAS-BLED (C-index ≈0.6).26 The ATRIA and HAS-BLED scores also performed similarly in a small study
of 937 patients in an outpatient anticoagulation clinic11 and in a recent meta-analysis, which reported low sensitivity for major bleeding events in high-risk categories for all three scores.12 The
suboptimal performance observed when applying existing scores
to external observational populations may in part stem from methodological limitations of the original derivation studies. The
HAS-BLED score, for example, was derived based on only 53 major
bleeding events, and a sizable proportion (25%) of information was
missing on major bleeds during follow-up.9 Anticoagulation and risk
factors in atrial fibrillation study authors noted that their score was
based on limited covariates from a computerized database that
lacked information on potentially important risk factors such as
blood pressure and antiplatelet use.10 Additionally, the claims data
used in the ATRIA study may be less sensitive for identifying major
bleeds, which may in part explain the substantially higher event rates
observed in ROCKET at every level of the ATRIA score. Existing
scores are further limited by elements that may not be readily accessible by the practitioner. Complete calculation of HAS-BLED,
for example, requires information on ‘labile INR’, which is difficult
to measure and not relevant to patients taking novel oral
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12.3 (9.0– 16.7)

14.9 (8.9– 25.3)
4.0

293

80
14 399
50
7411
7
Overall

12
581

173
6

36

6.8 (5.8– 8.1)
9.0 (7.2– 11.2)

*ORBIT bleeding risk score components (point value) ¼ Older than 74 (1), Reduced hemoglobin/Anemia (2), Bleeding history (2), Insufficient kidney function [,60 ml/min/1.73 meters2] (1), Treatment with Antiplatelet (1). Abnormal
hemoglobin (,13 mg/dL for males and ,12 mg/dL for females) or hematocrit (,40% for males and ,36% for females).

4.7

8.1
3096

2593
123

252
1719

1351
Medium (3)
4.7 (4.0– 5.6)

1901
822
1038
458
4
5

130
74

1351
3

123

2593

High (≥4)

2.4
8711
206
4341
2.3 (1.9– 2.9)
2.9 (2.3– 3.5)
3426
3131

Low (0 –2)
1.7 (1.2– 2.4)
2154

1701
1576
1
2

79
90

1064
0

37

Number of
major bleeds
Total
number
ORBIT bleeding
score* category
Bleeds per 100
patient-years (95% CI)
Patient-years

Number of
major bleeds
Total
number
ORBIT
bleeding score

Table 3

Outcomes registry for better informed treatment bleeding risk score and observed major bleeding rates

Patient-years

Bleeds per 100
patient-years

.............................................................................................................................................................................................................................................
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Table 4 C-statistics* (95% confidence intervals) for
score discrimination by study cohort
Score

ORBIT-AF
cohort

ROCKET-AF
cohort

Risk
categories

................................................................................
Full continuous
model

0.69 (0.67, 0.72) 0.63 (0.61, 0.65)

–

ORBIT score

0.67 (0.64, 0.69) 0.62 (0.60, 0.64) 0 –7

HAS-BLED score
ATRIA score

0.64 (0.62, 0.67) 0.59 (0.57, 0.61) 0 –9
0.66 (0.63, 0.68) 0.60 (0.58, 0.62) 0 –10

*C-index is calculated at 2 years.

anticoagulants or to those who have not had prior anticoagulation.
The ORBIT score addresses the limitations of existing scores
through inclusion of known risk factors for severe bleeding, elements that are relevant to all patients taking OAC, and derivation
in a large, national, contemporary population of AF with a large
number of major bleeding events.4,23,24
While bleeding risk estimation can be helpful in identifying highrisk AF patients for closer monitoring, it is important to note that
prior work has demonstrated a net clinical benefit of OAC even
in patients with high estimated bleeding risk.27,28 Further, while
risk scores provide important information to the clinician for estimating risk of adverse events, they represent only one consideration
relevant to therapeutic decision making. While several variables
identified as risk factors for major bleeding in prior studies were either unavailable (labile INR) or not associated with major bleeding in
this cohort (alcohol abuse), these may be important for the provider to consider on the individual patient level. Optimal treatment
strategies incorporate patient preferences and values, which may
differ from that of the physician. Results from a recent survey suggest that patients are prepared to sustain four major bleeds to avoid
a single stroke.29 However, as highlighted in the European Society of
Cardiology Consensus document on bleeding risk assessment,5
much of the existing evidence on patient preferences comes from
small studies with heterogeneous methods. Further work is needed
to describe patient preferences, perception of risk, and how the
format of information provided influences these.

Limitations
Our study has several limitations. First, not all components of each
score we evaluated were available in the ORBIT-AF or ROCKET-AF
databases. However, lack of data availability also limits application of
risk scores in clinical practice. Furthermore, HAS-BLED score
authors have promoted the score’s utility in non-VKA anticoagulated patients and others for whom INR data are not available.30 Second, while the ORBIT-AF study collects detailed clinical data on the
majority of known risk factors for major bleeding, it is possible that
other important risk factors exist and were not captured in our dataset. Third, while the ORBIT score includes the five risk factors that
were most strongly associated with major bleeding in our study,
additional factors may also be important in estimating patientspecific risk. Additionally, we validated the ORBIT score in a clinical
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Figure 1 Calibration plot of outcomes registry for better informed treatment, hypertension, abnormal renal/liver function, stroke, bleeding
history or predisposition, labile INR, elderly, drugs/alcohol concomitantly, and anticoagulation and risk factors in atrial fibrillation in the rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation
external validation cohort. This figure displays the major bleeding events rates per 100 patient-years and 95% confidence intervals observed in the
external validation rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation cohort vs. those previously published from the original derivation cohorts for each discrete score point value. The
highest risk categories for each score were combined to promote stable estimates as follows: outcomes registry for better informed treatment
(0, 1, 2, 3, ≥4), anticoagulation and risk factors in atrial fibrillation (0, 1, 2, 3, ≥4), and hypertension, abnormal renal/liver function, stroke, bleeding
history or predisposition, labile INR, elderly, drugs/alcohol concomitantly (0, 1, 2, ≥3). ORBIT-AF; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation; ROCKET-AF, Rivaroxaban Once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation; ATRIA, anticoagulation and risk factors in atrial fibrillation.

trial population, which represents a selected patient population; validation in broader international populations to assess generalizability is warranted. Finally, ORBIT-AF participating sites were selected
to be representative of the US national AF population; however, the
cohort may not be fully representative of all community practice. As
such, further external validation to assure the generalizability of the
ORBIT risk score would be informative.

Conclusions
The ORBIT bleeding score is a novel, user-friendly score to estimate
major bleeding risk among patients with AF and exhibits similar performance compared with a full predictive model. While ORBIT,
HAS-BLED, and ATRIA scores showed similar discrimination in an
external validation population, the ORBIT score showed superior
calibration and is more widely applicable than existing bleeding
scores.

Supplementary material
Supplementary material is available at European Heart Journal online.
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